What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025Blood

Renin-angiotensin-aldosterone system inhibitors exacerbate anemia in sickle cell disease

View Full Paper

Ask AI

Bookmark

Authors

Cross-sectional and longitudinal analysis shows RAASi use reduces hemoglobin levels in sickle cell disease, highlighting risks of treatment.

Anemia worsens in sickle cell disease with renin-angiotensin-aldosterone system inhibitors, impacting hemoglobin levels.
Median hemoglobin concentration is significantly lower with RAASi use, showing a mean difference of -0.31 g/dL on therapy.
Clinical trial data indicate that losartan therapy reduces hemoglobin concentrations in sickle cell disease patients.
Findings suggest careful consideration when using RAASi in sickle cell disease due to anemia risks.

Pappano et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Cross-sectional and longitudinal analysis shows RAASi use reduces hemoglobin levels in sickle cell disease, highlighting risks of treatment.